Table 3.
Multiple linear regression analysis of the association between five putative biomarker proteins and their combined value with clinical pathologic features
| Tumor variables |
P
value |
|||||
|---|---|---|---|---|---|---|
| ApoCI | C3a-desArg | Transthyretin | ApoAI | ApoH fragment | Combined parameter | |
| Grade (G1, n = 22; G2, n = 64; G3, n = 96) |
0.781 |
0.908 |
0.862 |
0.876 |
0.836 |
0.697 |
| Tumor size (T ≤2 cm; T >2 cm) |
0.314 |
0.867 |
0.004 |
0.921 |
0.516 |
0.018 |
| LN (positive, n = 79; negative, n = 78) |
0.182 |
0.503 |
0.397 |
0.119 |
0.499 |
0.016 |
| ER (positive, n = 131; negative, n = 50) |
0.550 |
0.756 |
0.151 |
0.517 |
0.124 |
0.341 |
| PR (positive, n = 121; negative, n = 63) |
0.723 |
0.774 |
0.010 |
0.171 |
0.340 |
0.825 |
| HER2 (positive, n = 38; negative, n = 133) | 0.509 | 0.280 | 0.968 | 0.018 | 0.733 | 0.087 |
ApoCI/AI/H, apolipoprotein CI/AI/H; C3a-desArg, C3a des-arginine anaphylatoxin; LN, lymph node involvement; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.